Notice of Intent to Sole Source – Life Technologies Corp.
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
The purpose of this acquisition is to purchase reagents and consumables that are needed to run Life Technologies instruments at the Department of Laboratory Medicine (DLM) at National Institutes of Health (NIH) Clinical Center (CC).
• Product Service Code: 6515 – Medical Instruments, Equipment, and Supplies
• NAICS Code: 339112 – Surgical and Medical Instrument Manufacturing
• Place of Performance: Bethesda, MD 20892 USA
POTS: 25-000661
Description:
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.
The National Institutes of Health (NIH) intends to award a fixed price purchase order to Life Technologies Corporation, located at 3175 Staley Rd, Grand Island, NY 14072, on a firm fixed price sole source award basis to provide reagents and consumables that are needed to run Life Technologies instruments at the Department of Laboratory Medicine (DLM) at National Institutes of Health (NIH) Clinical Center (CC).
Life Technologies Scientific is the sole-source manufacturer and supplier of the
consumables and kits that are used in the laboratory. There are other types of
kits that are on the market, however, they work differently than what have been
validated for our patients. These reagents have been fully validated for use in
BCR-ABL fusion assay, cKIT mutation assay and JAK2 mutation assay.
Switching to another system would entail lengthy validations and would alter
current results of our protocols. The department has been very conscientious
about cost savings and has thoroughly investigated and validated patient testing
using these consumables and reagents. The possibility of inconsistent data could
result from switching vendors and equipment. It could also necessitate additional
quality control mechanisms. This could cause potential delays in patient care,
protocols and incur unwarranted government expenditure and waste.
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.
Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to Kristin.nagashima@nih.gov by December 17, 2025 at 12pm EST.